Skip to main content

Table 1 Characteristics of HCC patients with and without portal vein invasion

From: C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion

Variables HCC with PV invasion
(n=83, 7.3%)
HCC without PV invasion
(n=1056, 92.7%)
P value
Gender    0.252
Male  71 (85.5%) 842 (79.7%)  
Female  12 (14.5%) 214 (20.3%)  
Age (years) 49 (20–72) 54 (19–82) <0.001
Etiology    0.447
HBV  63 (75.9%) 816 (77.6%)  
HCV  4 (4.8%) 54 (5.1%)
Alcohol  4 (4.8%) 19 (1.8%)
Non-B, non-C  10 (12.0%) 142 (13.5%)
Others  2 (2.4%) 20 (1.9%)
Locoregional therapy    0.070
None  64 (77.1%) 907 (85.9%)  
TACE  18 (21.7%) 127 (12.0%)
RFA  1 (1.2%) 13 (1.2%)
TACE and RFA  0 (0%) 9 (0.9%)
White blood cells (/uL) 5,730 (2,520–10,530) 5,460 (1,270–16,530) 0.103
Hemoglobin (g/dL) 14.3 (9.8–17.0) 14.2 (8.1–16.8) 0.360
Platelet counts (/uL) 174,000 (80,000–627,000) 160,000 (19,000–708,000) 0.125
INR 1.09 (0.93–1.32) 1.08 (0.84–1.59) 0.901
Albumin (g/dL) 4.1 (2.9–5.0) 4.1 (2.1–5.3) 0.423
Total bilirubin (mg/dL) 0.7 (0.2–3.5) 0.7 (0.2–4.3) 0.310
AST (U/L) 43 (23–283) 35 (14–353) <0.001
ALT (U/L) 44 (17–288) 35 (13–385) 0.002
ALP (U/L) 93 (38–233) 79 (32–562) <0.001
GGT (U/L) 105 (17–1,442) 49 (8–1,322) <0.001
Creatinine (mg/dL) 0.86 (0.44–1.27) 0.88 (0.42–5.87) 0.586
Estimated GFR (mL/min) 98.6 (72.2–149.2) 89.4 (5.7–189.0) 0.003
CRP (mg/dL) 0.27 (0.04–28.62) 0.13 (0.01–22.24) 0.048
AFP (ng/mL) 813.2 (1.8–200,000) 26.4 (1.0–2,121,720) <0.001
PIVKA-II (mAU/mL) 482.0 (12–1,200) 42.0 (2–2,000) <0.001
Operation    <0.001
Anatomical  61 (73.5%) 540 (51.1%)  
Non-anatomical  22 (26.5%) 516 (48.9%)
Hepatectomy    <0.001
Major  50 (60.2%) 274 (25.9%)  
Minor  33 (39.8%) 782 (74.1%)
Resection    0.035
R 0 77 (93.9%) 1029 (98.0%)  
R 1 5 (6.1%) 21 (2.0%)
Margin (mm) 10 (1–53) 10 (1–80) 0.331
Maximum tumor size (mm) 6.0 (1.4–17.5) 3.3 (0.2–21.0) <0.001
Grade    0.001
1 and 2  67 (80.7%) 976 (92.4%)  
3 and 4  16 (19.3%) 80 (7.6%)
Cirrhosis 40 (48.2%) 468 (44.3%) 0.494
Capsule formation    <0.001
None  33 (39.8%) 69 (6.6%)  
Complete  35 (42.2%) 875 (83.2%)
Partial  15 (18.1%) 108 (10.3%)
Bile duct invasion 7 (8.4%) 24 (2.3%) 0.005
Serosa involvement 2 (2.4%) 12 (1.1%) 0.272
Intrahepatic metastasis 41 (49.4%) 112 (10.6%) <0.001
Multicentric occurrence 1 (1.2%) 57 (5.4%) 0.118
Hospitalization 9 (5–53) 9 (3–102) 0.932
Duration of Follow-up (months) 18 (5–68) 32 (3–82) <0.001
  1. AFP, Alpha-fetoprotein; ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CRP, C-reactive protein; GFR, Estimated glomerular filtration rate; GGT, Gamma-glutamyl transferase; HBV, Hepatitis B virus; HCV, Hepatitis C virus; INR, International normalized ratio; PIVKA-II, Protein induced by vitamin K antagonist-II; PV, Portal vein; RFA, Radiofrequency ablation; TACE, Transarterial chemoembolization.